Twinstrand Therapeutics

Twinstrand Therapeutics operates as a biopharmaceutical company which engages in the discovery, development.

Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.